TP53 Y234C

CI-VAR-00004786Explore in graph →NP_000537.3:p.Tyr234CysNM_000546.5:c.701A>GClinVar 127820 CIViC 1068 rs587780073

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Ovarian Neoplasm1
TP53 Y234C	Carboplatin + CisplatinSubstitutes	Predictive	C	Supports Resistance	—	accepted	EID2745 Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A … (full text at CIViC) PMID 11595686 · Reles et al., 2001 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
127820	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts	2	Li-Fraumeni syndrome; Hereditary cancer-predisposing syndrome; Ovarian neoplasm; Li-Fraumeni syndrome 1; Neoplasm	germline/somatic	11	Dec 30, 2025	clinvar